DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?

Information source: Vanderbilt University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bipolar Disorder

Intervention: Risperdal (risperidone) Consta (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Vanderbilt University

Official(s) and/or principal investigator(s):
Richard C Shelton, M.D., Principal Investigator, Affiliation: Vanderbilt University


This study will evaluate the relative effectiveness of risperidone Consta injections occurring every 2 weeks in contrast to treatment as usual in preventing symptomatic relapse and rates of rehospitalization or admission into respite care for bipolar patients. Hypothesis: Risperdal Consta injections every 2 weeks will reduce the number of symptomatic relapses into mania, hypomania, mixed state, or depression, as shown by key indicators that include symptomatic relapse, rehospitalizations, emergency or urgent care visits, respite care, and intensive outpatient treatment as compared to treatment as usual.

Clinical Details

Official title: Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The principal outcome will be number of events normalized to unit time; this will be calculated by dividing the number of relapse related events by the number of months of participation.

Detailed description: Bipolar disorder arguably represents the most difficult to treat of all psychiatric disorders. In fact, long-term stabilization is more the exception than the rule, and the majority of patients experience frequent relapses of illness. Studies have shown that both bipolar I and II patients spend about half of their weeks in a significant symptomatic state. Relapses and persistent illness result in substantial morbidity, mortality, and disability. Symptomatic recurrences happen as a result of breakthrough symptoms during active treatment and intermittent non-adherence. Therefore, enhanced control of symptoms, coupled with ensured adherence, is very likely to improve the long-term outcome of this difficult-to-treat condition. Risperidone has been shown to be effective in controlling symptoms of acute mania or mixed state in two registration monotherapy and one combination treatment study with lithium or valproate, as well as several smaller trials. However, longer-term treatment studies are relatively lacking. As well, although Risperdal Consta(TM) has been shown to be of benefit in prevention of relapse in patients with schizophrenia, relatively little longer-term data in bipolar disorder is available. Nonetheless, both risperidone and Risperdal Consta (TM) are likely to be highly efficacious for the maintenance prevention of relapse in bipolar disorder. Moreover, Risperdal Consta(TM) helps to ensure longer-term treatment effectiveness, both by better adherence and improved control of symptoms. The present study is intended to determine whether Risperdal Consta(TM) injections, added to ongoing pharmacotherapy, will improve outcome relative to treatment as usual.


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Be physically healthy

- 18-60 years of age

- Have a DSM-IV diagnosis of bipolar disorder in any phase, but without current

psychotic features; with a history of symptomatic relapse on four or more occasions over the last year prior to the initiation of study for the treatment of bipolar disorder (type I or II, manic, hypomanic, mixed, or depressive type), with at least 1 in the previous 6 months.

- Have a screening HAM-D17 score of > 8 or a YMRS > 8.

Exclusion Criteria:

- Have any medical condition that would preclude treatment with Risperdal Consta(TM)

- Have type 2 diabetes

- Have hyperlipidemia (baseline total cholesterol >280)

- Have any clinically significant unstable medical condition

- Have currently active psychotic symptoms (hallucinations or delusions) or carry a

diagnosis of another psychotic disorder (schizophrenia, schizoaffective disorder, delusional disorder)

- Have a documentable history of non-response to Risperidal Consta (TM)

- Have a score of 4 on the suicide item (item 3) of the HAM-D scale and/or a

determination by the investigator of significant suicide risk

- Require hospitalization between the screening and baseline visits, or require

hospitalization immediately following baseline

- Have a medical contraindication or hypersensitivity to risperidone or Risperdal

Consta (TM)

Locations and Contacts

Mental Health Cooperative, Inc., Nashville, Tennessee 37228, United States
Additional Information

Starting date: November 2007
Last updated: June 1, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017